Based on these results, a clinical trial testing the combination of the PARP inhibitor olaparib and a PI3K inhibitor (pan-P110 BKM-120 or P110α specific BYL719) was initiated for breast and ovarian cancer (NCT01623349). The gene discussed is PIK3CA; the disease is ovarian cancer.